Pituitary metastasis: an unexpected complication in advanced cancer
Natthaphon Wonghakaeo, Thiti Snabboon
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPituitary Gland Disorders and Treatments · Glioma Diagnosis and Treatment · Brain Metastases and Treatment
Image in medicine
A 57-year-old man with metastatic breast cancer presented with a four-month history of polyuria, which was diagnosed as diabetes insipidus (DI). Further hormonal evaluation revealed concurrent hypothyroidism and hypocortisolism. Magnetic resonance imaging demonstrated a pituitary lesion with an absent posterior bright spot, suggesting a metastatic lesion. Unfortunately, the patient died from uncontrolled advanced disease one month later. Pituitary metastasis is rare but increasingly recognized due to advances in imaging and treatment. Breast and lung cancers are the most common primary malignancies. Clinical presentations vary from asymptomatic cases to visual field defects or pituitary dysfunction caused by compression of adjacent structures. Diabetes insipidus is the most common endocrine abnormality, with anterior hypopituitarism in 25-45% of cases. Diagnosing pituitary metastasis can be challenging, as it may be mistaken for pituitary adenoma. Key magnetic resonance imaging (MRI) findings indicative of metastasis include dumbbell-shaped lesions, stalk thickening, erosion of the sella turcica, and the absence of the posterior pituitary bright spot. The prognosis is generally poor, with a median survival of 12.9 months, and no treatment has significantly improved survival. Therefore, clinicians should consider pituitary metastasis, especially in patients with advanced malignancies presenting with DI.
magnetic resonance imaging findings; A) sagittal T1-weighted image showing a 1 cm hypointense lesion in the mid-posterior part of the pituitary gland (arrow), with an absent posterior bright spot (curved arrow); B) coronal T2-weighted image demonstrating a hyperintense lesion (arrow); C, D) post-gadolinium sagittal and coronal T1-weighted images revealed a heterogeneous enhancement lesion (arrow) with a normal-appearing pituitary stalk (dashed arrow); metastatic lesions were also noted in the clivus and occipital bone